Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lipocine Inc LPCN

Healthcare Biotechnology
Lipocine Inc. is a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery to develop differentiated products for Central Nervous System (CNS) disorders. Its clinical development candidates include: LPCN 1154, oral brexanolone, for treatment of postpartum depression, LPCN 2101 for epilepsy, LPCN 2203 for essential tremor... see more

Recent & Breaking News (NDAQ:LPCN)

Harwood Feffer LLP Announces Investigation of Lipocine Inc.

Business Wire January 29, 2018

Mid-Day Market Update: Dow Surges 150 Points; Lipocine Shares Plummet

Benzinga.com  January 11, 2018

Lipocine Announces Outcome of FDA Advisory Committee Meeting for TLANDO™, Testosterone Replacement Therapy in Adult Males with Hypogonadism

PR Newswire January 10, 2018

Benzinga Pro's 6 Stocks To Watch Today

Benzinga.com  January 10, 2018

Attention Biotech Investors: Brace For These January PDUFA Events

Benzinga.com  December 30, 2017

U.S. FDA Extends Review for TLANDO™; Advisory Committee Meeting Date of January 10, 2018 Remains Unchanged

GlobeNewswire November 17, 2017

Lipocine Announces Financial and Operational Results for the Third Quarter and Nine Months Ended September 30, 2017

GlobeNewswire November 8, 2017

FDA Advisory Committee Scheduled to Review TLANDO™ on January 10, 2018

GlobeNewswire October 18, 2017

Stocks Under Scanner in the Generic Drugs Space -- Akorn, Pacira Pharma, Rigel Pharma, and Lipocine

PR Newswire September 26, 2017

Lipocine Announces Motions Decision by USPTO in Interference Against Clarus

GlobeNewswire September 21, 2017

Lipocine Announces FDA Advisory Committee Meeting for TLANDO™

GlobeNewswire September 20, 2017

Lipocine to Present at the Ladenburg Thalmann 2017 Healthcare Conference

GlobeNewswire September 19, 2017

Lipocine to Present at the Rodman & Renshaw 19th Annual Global Investment Conference

GlobeNewswire September 5, 2017

Daily Technical Summary Reports on Generic Drugs Stocks -- Collegium Pharma, Momenta Pharma, Lipocine, and Diplomat Pharma

PR Newswire August 23, 2017

Lipocine Announces FDA Acknowledgement of TLANDO™ (“LPCN 1021”) NDA Resubmission; PDUFA Goal Date, February 8, 2018

GlobeNewswire August 14, 2017

Lipocine Resubmits NDA for Its Oral Testosterone Product Candidate, LPCN 1021, for Treatment of Hypogonadism

GlobeNewswire August 9, 2017

Lipocine Announces Financial and Operational Results for the Second Quarter and Six Months Ended June 30, 2017

GlobeNewswire August 7, 2017

Lipocine to Present at the Canaccord Genuity 37th Annual Growth Conference

GlobeNewswire August 2, 2017

Lipocine Announces Submission of SPA on LPCN 1107, an Oral Alternative for the Prevention of Preterm Birth

GlobeNewswire June 26, 2017

Mid-Afternoon Market Update: Fang Drops After Q1 Results; Invivo Therapeutics Shares Surge

Benzinga.com  June 20, 2017